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Induction of Remission is Difficult due to Frequent Relapse 
during Tapering Steroids in Korean Patients with Polymyalgia 
Rheumatica
Polymyalgia rheumatica is an inflammatory disease affecting elderly and involving the 
shoulder and pelvic girdles. No epidemiological study of polymyalgia rheumatica was 
conducted in Korea. We retrospectively evaluated patients with polymyalgia rheumatica 
followed up at the rheumatology clinics of 10 tertiary hospitals. In total 51 patients, 36 
patients (70.6%) were female. Age at disease onset was 67.4 yr. Twenty-three patients 
(45.1%) developed polymyalgia rheumatica in winter. Shoulder girdle ache was observed 
in 45 patients (90%) and elevated erythrocyte sedimentation rate (> 40 mm/h) in 49 
patients (96.1%). Initial steroid dose was 23.3 mg/d prednisolone equivalent. Time to 
normal erythrocyte sedimentation rate was 4.1 months. Only 8 patients (15.7%) achieved 
remission. Among 41 patients followed up, 28 patients (68.3%) had flare at least once. 
Number of flares was 1.5 ± 1.6. The frequency of flare was significantly lower in patients 
with remission (P = 0.02). In Korea, polymyalgia rheumatica commonly develops during 
winter. Initial response to steroid is fairly good, but the prognosis is not benign because 
remission is rare with frequent relapse requiring long-term steroid treatment.
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INTRODUCTION
Polymyalgia rheumatica (PMR) is an inflammatory condition 
affecting elderly people and characterized by aching and stiff-
ness in shoulder and pelvic girdles. Its occurrence is not rare, 
and reported prevalence rates from European data range from 
12.7 to 112.6 cases per 100,000 inhabitants, with a geographical 
gradient making the disease more frequent in the north (1, 2). 
Although PMR is generally regarded as a benign disease with no 
adverse impact on long-term survival, most patients with PMR 
require long-term steroid therapy, which is associated with var-
ious side effects (3, 4). 
  Diagnosis of PMR is based on a combination of clinical symp-
toms, raised acute-phase reactants, exclusion of other disease, 
and response to steroids. Clinical symptoms and laboratory re-
sults are not disease specific; therefore, a differential diagnosis 
is needed in order to exclude neoplastic and other rheumato-
logic diseases, like elderly rheumatoid arthritis (RA) and sero-
negative symmetrical synovitis with pitting edema. Therefore, a 
few sets of diagnostic criteria for PMR were proposed and have 
been used in clinical practice (2, 5-7).
  In most cases of PMR, an initial dose of 10-20 mg per day of 
prednisone or equivalent is adequate in the absence of associ-
ated giant cell arteritis. The response to steroid is usually rapid, Kim H-A, et al.  •  Polymyalgia Rheumatica in Korea
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with complete or nearly complete resolution of musculoskeletal 
aching and stiffness within a few days (5, 8). A treatment course 
of 1-2 yr is often required. However, some patients might need 
low doses of steroid for several years. Therefore, methotrexate 
has been proposed as a steroid-sparing drug in treatment of PMR, 
with conflicting results (9-11). Some studies have reported that 
anti-tumor necrosis factor (TNF) agents had a steroid-sparing 
effect in treatment of patients who are resistant to steroid thera-
py (12-14).
  Data on the disease course, clinical features, and outcome of 
PMR have been described in various parts of the world (15-18). 
However, data on the disease course, ultimate outcome, and ther-
apeutic response of PMR in Korea are limited.
  We describe the clinical features of 51 Korean patients with 
PMR who were treated in 10 tertiary hospitals, and analyze the 
therapeutic response and remission related factors. 
MATERIAL AND METHODS
All patients with a diagnosis of PMR who had been followed up 
at the rheumatology clinics of 10 university-based tertiary hos-
pitals were retrospectively evaluated. Diagnosis was based on 
Bird’s criteria for PMR (6): 1) bilateral shoulder pain or stiffness, 
or both; 2) onset of illness within 2 weeks; 3) initial erythrocyte 
sedimentation rate (ESR) greater than 40 mm/h; 4) duration of 
morning stiffness greater than 1 h; 5) age 65 yr or older; 6) depres-
sion or weight loss, or both; and 7) bilateral upper arm tender-
ness. A diagnosis of probable PMR was made if any three or more 
of these seven criteria were fulfilled. Patients who had other con-
nective tissue disorders like RA and fibromyalgia, systemic in-
fection or abnormal levels of serum creatinine kinase or thyroid-
stimulating hormone were excluded. After a detailed history and 
physical examinations, all patients underwent a series of labo-
ratory tests, including complete blood count (CBC), ESR, C-re-
active protein (CRP), rheumatoid factor (RF), anti-nuclear anti-
body (ANA), liver function tests, and urinalysis. Clinical charac-
teristics, including demographic features, duration of illness be-
fore diagnosis, clinical features, treatment, length of follow-up, 
flares and complications were recorded using a standardized 
form. Flares were defined as an increase in activity of PMR symp-
toms sufficient to warrant an increase in steroid dose (16). Remis-
sion was defined as the absence of articular and systemic labo-
ratory evidence of disease activity for at least two consecutive 
months without any kind of drugs and no recurrence. 
  Statistical analyses were performed using the SPSS software, 
version 12.0 (Chicago, IL, USA). All data were expressed as the 
mean ± SD and a P value of less than 0.05 was regarded as sig-
nificant. Predicting factors for remission were assessed using a 
chi-squared-test and Mann-Whitney U test. 
Ethics statement
This study was approved by the institutional review board of Ajou 
University Hospital (AJOU-MED-MDB-11-180). Informed con-
sent was waived by the board.
RESULTS
Of a total of 51 patients with PMR, 36 patients (70.6%) were female. 
Age at disease onset ranged from 49 to 89 yr, with a mean of 67.4 
± 10.6 yr. Symptom duration before diagnosis was 4± 11.7 months 
and the follow-up period was 27.6 ± 30.5 months (Table 1).
  Symptoms of PMR developed in 10 patients (19.6%) in spring, 
13 (25.5%) in summer, 5 (9.8%) in fall, and 23 (45.1%) in winter. 
Shoulder girdle ache was observed in 45 patients among 50 pa-
tients (90%) and pelvic girdle ache was present in 28 patients 
among 47 patients (59.6%). Other manifestations, in order of 
decreasing frequency, included peripheral arthritis in 29 patients 
among 46 patients (64%), morning stiffness in 22 patients among 
47 patients (46.8%), weight loss in 12 patients among 46 patients 
(26.1%), fever in 13 patients (25.5%), headache in 11 patients 
among 47 patients (23.4%), and depression in 10 patients among 
47 patients (21.3%). There were no cases of biopsy-confirmed 
giant cell arteritis.
  Table 2 shows the results of selected laboratory tests. Specifi-
Table 1. Clinical characteristics in 51 patients with polymyalgia rheumatica
Parameters Mean or number (%)
Age at diagnosis (yr) 67.4 ± 10.6 
Sex (F/M) 36 (70.6)/15 (29.4) 
Symptom duration (months)      4 ± 11.7 
Follow-up period (months) 27.6 ± 30.5
Shoulder girdle pain 45/50 (90) 
Hip girdle pain    28/47 (59.6) 
Peripheral arthritis 29/46 (64) 
Morning stiffness    22/47 (46.8) 
Weight loss     12/46 (26.1) 
Headache     11/47 (23.4) 
Fever         13 (25.5)
Depression    10/47 (21.3) 
Giant cell arteritis 0/51 (0)
Table 2. Laboratory findings in 51 patients with polymyalgia rheumatica
Features Number (%)
Elevated white blood cell count (≥ 10,000/µL)         13 (25.5) 
Thrombocytosis (≥ 400,000/µL)         21 (41.2) 
Anemia (< 10.0 g/dL)           7 (13.7) 
Elevated erythrocyte sedimentation rate (> 40 mm/h)         49 (96.1) 
Elevated C-reactive protein (> 0.8 mg/dL)         47 (92.2) 
Elevated liver function abnormality
   (AST  ≥ 40 U/L or ALT  ≥ 41 U/L)         11 (21.6) 
Decreased albumin (< 3.5 mg/dL)         20 (39.2) 
Elevated alkaline phosphatase (> 120 U/L)      26 (51) 
Positive rheumatoid factor  14/50 (28) 
Positive antinuclear antibody  19/50 (38)
AST, aspartate transaminase; ALT, alanine transaminase.Kim H-A, et al.  •  Polymyalgia Rheumatica in Korea
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cally, an elevated ESR (> 40 mm/h) was observed in 49 patients 
(96.1%), an elevated CRP (> 0.8 mg/dL) in 47 patients (92.2%), 
leukocytosis (≥ 10,000/μL) in 13 patients (25.5%), thrombocy-
tosis (≥ 400,000/μL) in 21 patients (41.2%), elevated alkaline 
phosphatase in 26 patients (51%), positive ANA in 19 patients 
(38%), and positive RF in 14 patients (28%). RF titers of positive 
patients were low (14-27.3 IU/mL). The ANA titer was  < 1:320, 
except for one case. For ANA positive patients, the diagnosis of 
SLE could be excluded according to American College of Rheu-
matology criteria.
  Drugs used singly or in combination included oral steroids 
(50 patients, 98%), non-steroid anti-inflammatory drugs (34 
patients, 66.7%), and disease modifying antirheumatic drugs 
(DMARDs) (26 patients, 51%). Methotrexate was the most com-
monly used DMARD (16 patients, 31.4%); however, other DM-
ARDs were used, including hydroxychloroquine in 12 patients 
(23.5%) and sulfasalazine in 3 patients (5.9%). Initial steroid dose 
was 23.3 ± 11.5 mg prednisolone equivalent. Time to normal 
ESR was 4.1 ± 5.4 months. 
  Malignancy was diagnosed in six patients (11.8%). Malignan-
cies preceded PMR in five patients (three patients, stomach can-
cer 2, 4, and 10 yr ago; one patient, prostatic cancer 7 yr ago and 
sigmoid cancer 4 months ago; one patient, colon cancer 8 yr ago). 
Patients diagnosed as PMR did not experience cancer recur-
rence. One patient developed ovarian cancer 1 yr after diagno-
sis of PMR. 
  During the follow-up period (27.6 ± 30.5 months), only 8 pa-
tients had stopped steroids, 10 patients were lost to follow-up, 
and 33 patients still received steroids. Of the 41 patients, 28 (68.3 
%) had flare at least once during the follow-up period. Number 
of flares was 1.5 ± 1.6. Follow-up duration of eight patients de-
fined as remission was 26.5 ± 17.9 months, and their flare fre-
quency was 0.5 ± 0.5. Their cumulative steroid dose was 2,306.6 
± 1,314.6 mg prednisolone equivalent. 
  Although the number of patients with remission was small, 
we evaluated clinical features and treatment between patients 
with remission and patients without remission (Table 3). No dif-
ference was observed in follow-up duration and clinical features. 
In addition, no significant difference was observed in initial ste-
roid dosage and cumulative dose of steroids between them. How-
ever, the frequency of flare was significantly higher in patients 
without remission (P = 0.02).
  Evaluation of clinical features and treatment between patients 
treated with methotrexate and patients treated without metho-
trexate showed no difference in follow-up duration and clinical 
features. In addition, no significant difference was observed in 
initial steroid dosage. However, patients treated with methotrex-
ate had higher cumulative steroid dosage (P = 0.046).
DISCUSSION
No epidemiological study of PMR in the Korean population has 
been conducted. Given the lack of awareness and the absence 
of biomarkers to aid in clinical diagnosis, it is possible that we 
are under diagnosing PMR. Therefore, in the present study, we 
described the clinical features of 51 Korean patients with PMR 
and analyzed the therapeutic response and remission related 
factors.
  PMR is an inflammatory disease that characteristically affects 
old people and women more often than man. In this study, the 
mean age at disease onset was 67.4 yr, and 70.6% of patients 
Table 3. Predicting factors for remission in 41 patients with polymyalgia rheumatica
Factors
Patients with  
remission 
No. (%) or 
mean ± SD 
Patients without 
remission 
No. (%) or 
mean ± SD 
 P 
 value
Number of patients 8 33
Fever    1 (12.5) 10 (30.3)   0.416
Weight loss    3 (37.5)   8 (19.5) 0.68
Depression 2 (25)   8 (19.5)   0.676
Headache 4 (50)   6 (18.2)   0.181
Peripheral arthritis 4 (50)   8 (19.5)   0.394
Hip girdle pain 2 (25) 12 (36.4)   0.684
Morning stiffness duration (min)      75 ± 123.2      96.5 ± 269.2   0.829
Follow-up duration (months) 26.5 ± 17.9    36.6 ± 36.7   0.554
Flare frequency 0.5 ± 0.5    1.9 ± 1.8 0.02
Initial VAPS 6.3 ± 2.2    6.1 ± 2.3   0.496
ESR (mm/h) 87.7 ± 21.1 69.6 ± 27   0.069
CRP (mg/dL) 8.9 ± 5.3    7.2 ± 7.6   0.534
Duration to normal ESR (months)    5 ± 3.3    3.5 ± 5.3   0.472
Initial steroid dose (mg/d) 25.6 ± 15.9 21.7 ± 10   0.371
Cumulative steroid dose (mg) 2306.6 ± 1314.6   6523.5 ± 10241   0.288
DMARDs medication 5 (62.5) 22 (66.7)     1.0
Methotrexate medication 1 (12.5) 15 (45.5)   0.224
VAPS, visual analogue pain score; ESR, erythrocyte sedimentation rate; CRP, C-reactive 
protein; DMARDs, disease modifying antirheumatic drugs. These data were assessed 
using χ2-test and Mann-Whitney U test.
Table 4. Clinical and laboratory findings among the Korean cohort compared with 
Caucasian, Chinese and Japanese series 
Parameters
Korean  
cohort  
No. (%) or 
mean ± SD
Caucasian  
cohort (21)  
No. (%) or 
mean ± SD
Chinese  
cohort (17)  
No. (%) or 
mean ± SD
Japanese  
cohort (15)  
No. (%) or 
mean ± SD
Total patients 51 213 44 32
Age (yr) 67.4 ± 10.6      70.3 75.8 ± 9.6    72.3
Females          36 (70.6)         124 (70.5)      15 (46.9)
Shoulder girdle pain 45/50 (90)  178/196 (90.8)  42 (95.5)   25 (78)
Hip girdle pain     28/47 (59.6)    82/213 (38.5) 11/32 (34)
Peripheral arthritis 29/46 (64)   24 (75)
Morning stiffness    22/47 (46.8)  147/173 (84.9)  30 (68.2)   25 (78)
Weight loss or 
   depression
18/50 (36) 85/213 (40)  13 (29.5)     8 (25)
Fever         13 (25.5)     8 (25)
ESR (> 40 mm/h)         49 (96.1)  158/165 (95.7) 44 (100)
CRP (> 0.8 mg/dL)         47 (92.2)
Positive RF 14/50 (28)    8 (18.1)      3 (9.3)
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor.Kim H-A, et al.  •  Polymyalgia Rheumatica in Korea
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were women, similar to previous studies (19, 20). Table 4 shows 
a summary of the clinical and laboratory data of Korean patients, 
compared to those reported in Caucasian (21), Chinese (17), 
and Japanese patients (15). Shoulder girdle pain, weight loss, 
and depression were prevalent symptoms, similar to other re-
ports (15-17, 21). Incidences of morning stiffness and peripher-
al arthritis were lower; however, the incidence of hip girdle pain 
was higher. These differences could be explained by racial differ-
ences and different natures of study. In this study, some patients 
with headache or fever were evaluated with temporal artery bi-
opsy. However, there was no biopsy-proven giant cell arteritis. 
Giant cell arteritis is the most frequent type of vasculitis in west-
ern countries, and European population-based studies of PMR 
have demonstrated the presence of biopsy-proved giant-cell ar-
teritis in 16 to 21 percent of patients (5). However, giant cell arte-
ritis is very uncommon in Asian population. The prevalence of 
giant cell arteritis in Japan was only 1.47 per 100,000 populations 
(22). There has been no study evaluating the incidence of giant 
cell arteritis in PMR patients in Asia.
  Elevated levels of ESR, CRP, and alkaline phosphatase were 
the most frequent laboratory findings. In addition, the frequen-
cies of thrombocytosis and hypoalbuminemia were high. Fre-
quencies of positive RF and ANA were higher than in previous 
reports (15, 23). However, their titers of RF were low. In addition, 
the ANA titer was  < 1:320, except for one case. 
  Previous findings related to seasonality have been somewhat 
inconsistent; however, seasonal patterns of incidence of PMR 
have been proposed as evidence to support an infectious etiol-
ogy (4). Clustering of diagnoses in the early summer months has 
been reported, while other studies have reported peaks in the 
winter months (4, 24, 25). However, other studies have reported 
no seasonal pattern (26, 27). In this study, we observed higher 
rates in the winter. These findings support an infectious etiology 
related to seasonal variation in incidence. 
  Steroid is the drug of choice in treatment of PMR. In the ab-
sence of giant cell arteritis, an initial dosage of 10-20 mg/day of 
prednisone or equivalent is adequate in most cases (5). Steroids 
are often needed for two to three years, and a subset of patients 
may relapse within 10 yr and require longer courses of treatment 
(28). A recent study reported that a higher plasma viscosity in 
PMR increases the risk of prolonged steroid therapy and late gi-
ant cell arteritis. The authors of the study also suggested that start-
ing patients on  > 15 mg prednisolone showed an association 
with prolonged steroid treatment (16). Adjuvant steroid sparing 
agents, such as methotrexate and anti-TNF agents, have been 
suggested for prevention of steroid related adverse events (9-13). 
Findings from a randomized controlled trial have suggested that 
methotrexate can be effective in treatment of PMR when the drug 
is started at disease onset and given for at least 1 yr at a dose of 
at least 10 mg per week (11). Two pilot studies reported on a ste-
roid-sparing effect of anti-TNF agents (infliximab and etaner-
cept) in patients who were resistant to steroid therapy (12, 14). 
However, a recent randomized controlled trial showed that inf-
liximab was ineffective in newly diagnosed patients with PMR 
(29). In this study, only one patient did not use steroid because 
of patient denial. Initial steroid dose was 23.3 ± 11.5 mg pred-
nisolone equivalent and the response was good, with improve-
ment of symptoms and normalization of ESR in 4.1± 5.4 months. 
Methotrexate was the most commonly used DMARDs (16 pa-
tients, 31.4%). Patients treated with methotrexate showed a high-
er cumulative steroid dosage than those who were not (P =  
0.046). These results could be explained by the fact that metho-
trexate was needed for control of disease activity in steroid de-
pendent patients.
  Some patients have a more chronic, relapsing course and may 
require low doses of steroid for several years. Two recent studies 
reported a relapse frequency of 50% in patients with PMR (25, 
29). Another study showed that increased initial doses of steroids 
and faster tapering were substantial predictors of relapse. There-
fore, they recommended keeping the initial steroid dose as low 
as possible, and that it should be discontinued slowly (28). Other 
studies suggested that persistently raised concentrations of CRP 
and interleukin 6 were helpful in identification of patients with 
relapsing disease (30). In this study, 28 patients (68.8%) had flare 
at least once during the follow-up period. The number of flares 
was 1.5 ± 1.6. Flare frequency of our patients was higher than 
that reported in previous studies. These differences could be 
explained by different flare or relapse standards. Kremers et al. 
(28) defined relapse as an exacerbation of PMR symptoms re-
quiring an increase in steroid dose  ≥ 5 mg/d occurring at least 
30 days after the incidence rate. Salvarani et al. (30) defined re-
lapse or recurrence as reappearance of clinical symptoms in as-
sociation with elevated ESR or CRP in a patient receiving steroids 
or after discontinuation of treatment. We evaluated clinical fea-
tures in patients with PMR according to achievement of remis-
sion. The frequency of flare was significantly higher in patients 
without remission than those with remission (P = 0.02). These 
results suggest that whether flare develops or not during taper-
ing of steroid could be an important predicting factor for remis-
sion. Larger prospective studies are needed in order to reveal 
therapeutic responses and prognostic factors of PMR in Korea.
  In conclusion, Korean patients commonly develop PMR in 
the winter and show more seropositivity, although the titer is 
low. The response to steroid is fairly good; however, tapering is 
not easy due to frequent flare. Approximately 15.7% of patients 
went into remission and the frequency of flare was significantly 
lower than patients without remission. More than half of patients 
required second-line treatment in order to reduce the steroid 
dose, which is most commonly methotrexate. The course of PMR 
is not benign, because remission is rare and relapse occurs fre-
quently with long-term steroid treatment. Kim H-A, et al.  •  Polymyalgia Rheumatica in Korea
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